Literature DB >> 28935992

Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.

S K Balasubramanian1, M Aly1, Y Nagata1, T Bat1, B P Przychodzen1, C M Hirsch1, V Adema1, V Visconte1, T Kuzmanovic1, T Radivoyevitch1, A Nazha2, S Mukherjee2, M A Sekeres2,3, J P Maciejewski1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28935992     DOI： 10.1038/leu.2017.295

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.

Authors:  O Abdel-Wahab; A Pardanani; R Rampal; T L Lasho; R L Levine; A Tefferi
Journal:  Leukemia       Date:  2011-04-26       Impact factor: 11.528

2.  Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.

Authors:  Celeste Holz-Schietinger; Doug M Matje; Norbert O Reich
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

3.  The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.

Authors:  David A Russler-Germain; David H Spencer; Margaret A Young; Tamara L Lamprecht; Christopher A Miller; Robert Fulton; Matthew R Meyer; Petra Erdmann-Gilmore; R Reid Townsend; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

4.  Dnmt3a is essential for hematopoietic stem cell differentiation.

Authors:  Grant A Challen; Deqiang Sun; Mira Jeong; Min Luo; Jaroslav Jelinek; Jonathan S Berg; Christoph Bock; Aparna Vasanthakumar; Hongcang Gu; Yuanxin Xi; Shoudan Liang; Yue Lu; Gretchen J Darlington; Alexander Meissner; Jean-Pierre J Issa; Lucy A Godley; Wei Li; Margaret A Goodell
Journal:  Nat Genet       Date:  2011-12-04       Impact factor: 38.330

Review 5.  The role of mutations in epigenetic regulators in myeloid malignancies.

Authors:  Alan H Shih; Omar Abdel-Wahab; Jay P Patel; Ross L Levine
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

6.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

Review 7.  DNMT3A in haematological malignancies.

Authors:  Liubin Yang; Rachel Rau; Margaret A Goodell
Journal:  Nat Rev Cancer       Date:  2015-02-19       Impact factor: 60.716

8.  Dynamics of clonal evolution in myelodysplastic syndromes.

Authors:  Hideki Makishima; Tetsuichi Yoshizato; Kenichi Yoshida; Mikkael A Sekeres; Tomas Radivoyevitch; Hiromichi Suzuki; Bartlomiej Przychodzen; Yasunobu Nagata; Manja Meggendorfer; Masashi Sanada; Yusuke Okuno; Cassandra Hirsch; Teodora Kuzmanovic; Yusuke Sato; Aiko Sato-Otsubo; Thomas LaFramboise; Naoko Hosono; Yuichi Shiraishi; Kenichi Chiba; Claudia Haferlach; Wolfgang Kern; Hiroko Tanaka; Yusuke Shiozawa; Inés Gómez-Seguí; Holleh D Husseinzadeh; Swapna Thota; Kathryn M Guinta; Brittney Dienes; Tsuyoshi Nakamaki; Shuichi Miyawaki; Yogen Saunthararajah; Shigeru Chiba; Satoru Miyano; Lee-Yung Shih; Torsten Haferlach; Seishi Ogawa; Jaroslaw P Maciejewski
Journal:  Nat Genet       Date:  2016-12-19       Impact factor: 38.330

9.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

10.  Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.

Authors:  M J Walter; L Ding; D Shen; J Shao; M Grillot; M McLellan; R Fulton; H Schmidt; J Kalicki-Veizer; M O'Laughlin; C Kandoth; J Baty; P Westervelt; J F DiPersio; E R Mardis; R K Wilson; T J Ley; T A Graubert
Journal:  Leukemia       Date:  2011-03-18       Impact factor: 11.528
View more
  5 in total

1.  DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks.

Authors:  Kartika Venugopal; Yang Feng; Pawel Nowialis; Huanzhou Xu; Daniil E Shabashvili; Cassandra M Berntsen; Prabhjot Kaur; Kathryn I Krajcik; Christina Taragjini; Zachary Zaroogian; Heidi L Casellas Román; Luisa M Posada; Chamara Gunaratne; Jianping Li; Daphné Dupéré-Richer; Richard L Bennett; Santhi Pondugula; Alberto Riva; Christopher R Cogle; Rene Opavsky; Brian K Law; Sumita Bhaduri-McIntosh; Stefan Kubicek; Philipp B Staber; Jonathan D Licht; Jonathan E Bird; Olga A Guryanova
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 12.531

2.  DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.

Authors:  Heidi L Casellas Román; Kartika Venugopal; Yang Feng; Daniil E Shabashvili; Luisa M Posada; Jianping Li; Olga A Guryanova
Journal:  Leuk Res       Date:  2020-05-13       Impact factor: 3.156

3.  DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.

Authors:  Majd Jawad; Michelle Afkhami; Yi Ding; Xiaohui Zhang; Peng Li; Kim Young; Mina Luqing Xu; Wei Cui; Yiqing Zhao; Stephanie Halene; Aref Al-Kali; David Viswanatha; Dong Chen; Rong He; Gang Zheng
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244

Review 4.  Alterations to DNMT3A in Hematologic Malignancies.

Authors:  Kartika Venugopal; Yang Feng; Daniil Shabashvili; Olga A Guryanova
Journal:  Cancer Res       Date:  2020-10-21       Impact factor: 13.312

5.  Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes.

Authors:  Giulia Falconi; Emiliano Fabiani; Alfonso Piciocchi; Marianna Criscuolo; Luana Fianchi; Elisa L Lindfors Rossi; Carlo Finelli; Elisa Cerqui; Tiziana Ottone; Alfredo Molteni; Matteo Parma; Stella Santarone; Anna Candoni; Simona Sica; Giuseppe Leone; Francesco Lo-Coco; Maria Teresa Voso
Journal:  Leukemia       Date:  2018-10-05       Impact factor: 11.528
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.